Výsledky vyhledávání - "Prajwal C. Boddu"

Akademický článek

Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase

Autor: Prajwal C. Boddu, Abhishek K. Gupta, Jung-Sik Kim, Karla M. Neugebauer, Todd Waldman, Manoj M. Pillai

Publikováno v: Communications Biology, Vol 4, Iss 1, Pp 1-9 (2021)

Boddu et al combined AAV-intron trap, CRISPR/Cas9 and inducible Cre-recombinase systems to introduce the oncogenic K700E mutation in SF3B1, which is a splicing factor commonly mutated in multiple cancers, with more than 90% efficiency. Their approach

Externí odkaz: https://doaj.org/article/a82081c24935453796100f3eab74b879

Zobrazit plný text záznamu

A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies

Autor: Prajwal C. Boddu, Jayastu Senapati, Farhad Ravandi‐Kashani, Elias J. Jabbour, Nitin Jain, Mary Ayres, Yuling Chen, Michael J. Keating, Hagop M. Kantarjian, Varsha Gandhi, Tapan M. Kadia

Publikováno v: Cancer. 129:580-589

Nelarabine is a purine nucleoside analogue prodrug approved for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) and lymphoblastic lymphoma (T-LBL). Although effective in R/R T-ALL, significant neurotoxicity is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b19c22e8223249a303b5744f3f41d94b
https://doi.org/10.1002/cncr.34570

Zobrazit plný text záznamu

Supplementary Data from Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Supplement (adjusted per last reviewer comment).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee191782a4e9799f5f8dbba012c1019
https://doi.org/10.1158/2159-8290.22532990

Zobrazit plný text záznamu

Transcription elongation defects link oncogenic splicing factor mutations to targetable alterations in chromatin landscape

Autor: Prajwal C Boddu, Abhishek Gupta, Rahul Roy, Barbara De La Pena Avalos, Ane Olazabal Herrero, Nils Neuenkirchen, Josh Zimmer, Namrata Chandhok, Darren King, Yashuhito Nannya, Seishi Ogawa, Haifan Lin, Matthew Simon, Eloise Dray, Gary Kupfer, Amit K. Verma, Karla M. Neugebauer, Manoj M Pillai

Publikováno v: bioRxiv

Transcription and splicing of pre-messenger RNA are closely coordinated, but how this functional coupling is disrupted in human disease remains unexplored. Here, we investigated the impact of non-synonymous mutations in SF3B1 and U2AF1, two commonly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fc52bc1a58f7506bad42b4fd807506b
https://europepmc.org/articles/PMC9994134/

Zobrazit plný text záznamu

Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase

Autor: Manoj M. Pillai, Todd Waldman, Prajwal C. Boddu, Jung-Sik Kim, Abhishek K. Gupta, Karla M. Neugebauer

Publikováno v: Communications Biology
Communications Biology, Vol 4, Iss 1, Pp 1-9 (2021)

Scalable isogenic models of cancer-associated mutations are critical to studying dysregulated gene function. Nonsynonymous mutations of splicing factors, which typically affect one allele, are common in many cancers, but paradoxically confer growth d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc5f797260fb0431bd46f0b5988501f4
http://europepmc.org/articles/PMC8514589

Zobrazit plný text záznamu

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Autor: Susan O'Brien, Graciela M. Nogueras-Gonzalez, Guillermo Garcia-Manero, Zeev Estrov, Srdan Verstovsek, Farhad Ravandi, Princy Yohannan Sam, Koji Sasaki, Preetesh Jain, Elias Jabbour, Prajwal C. Boddu, Tapan M. Kadia, Hycienth Ahaneku, Gautam Borthakur, Hagop M. Kantarjian, Jorge E. Cortes

Publikováno v: Blood Advances. 3:851-861

Cardiovascular or arteriothrombotic adverse events (CV- or AT-AEs) are reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). The incidence and characteristics across different TKI have not been systematic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1491166afe254b8ba8f32e885418610
https://doi.org/10.1182/bloodadvances.2018025874

Zobrazit plný text záznamu

SMACmimetics as potential cancer therapeutics in myeloid malignancies

Autor: Bing Z. Carter, Naveen Pemmaraju, Prajwal C. Boddu, Srdan Verstovsek

Publikováno v: British Journal of Haematology. 185:219-231

Evasion of apoptosis has been identified as one of the essential hallmarks of cancer. Inhibitor of apoptosis proteins (IAPs) are implicated in a host of myeloid malignancies, providing the rationale for strategies aimed at neutralizing IAPs to lower

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ed279800f15dcecd1d8f4d94163e9b4
https://doi.org/10.1111/bjh.15829

Zobrazit plný text záznamu

Indolent Presentations of Leukemic Lung Disease in Acute Myeloid Leukemia

Autor: Prajwal C. Boddu, Avi J. Cohen, Solmaz Ehtashimi-Afshar, Samir Gautam, Yukiko Kunitomo, Charles S. Dela Cruz, Peter A. Kahn, Alexa J. Siddon, Chace Avery, Rupak Datta, Seohyuk Lee, Patricia Valda Toro

BackgroundPatients with active acute myelogenous leukemia (AML) are at risk for leukemic infiltration (LI) into the lung and acute tumor lysis pneumopathy (ATLP) following chemotherapy. Fulminant presentations of these leukemic lung diseases are well

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::217520dfba96d714121bc97f743c2e19
https://doi.org/10.1101/2020.10.12.20211276

Zobrazit plný text záznamu

Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy

Autor: Elad Sharon, Richard F. Little, Jerald P. Radich, Prajwal C. Boddu, S. Percy Ivy, Beatriz Sanchez-Espiridion, Anne Caldwell, Gheath Alatrash, Amer M. Zeidan, Daniel Zelterman, Brent L. Wood

Publikováno v: Blood. 136:11-12

Study Background: Survival outcomes of older patients with AML are dismal with a 3-year survival of < 10%. The combination of hypomethylating agents (HMA) with venetoclax has emerged as the new standard of care for older unfit patients with AML, but

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0f4c43a3d1b35e66b681eb852879687
https://doi.org/10.1182/blood-2020-139752

Zobrazit plný text záznamu

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Autor: Jan Philipp Bewersdorf, Vijaya Raj Bhatt, Daniel J. DeAngelo, Huda S. Salman, Andre C. Schuh, Aaron D Goldberg, Pau Montesinos, Raajit K. Rampal, John Mascarenhas, Aref Al-Kali, Selina M. Luger, Martin S. Tallman, Michael R. Savona, Amy E. DeZern, Rami S. Komrokji, Roland B. Walter, Uwe Platzbecker, David P. Steensma, Francesco Onida, Rory M. Shallis, Amir T. Fathi, Eric Padron, Heiko Konig, Shyamala C. Navada, Prajwal C. Boddu, Alla Keyzner, Michael W. Deininger, Richard Stone, Eunice S. Wang, Blanca Xicoy Cirici, Paresh Vyas, Pierre Fenaux, Michal Bar-Natan, Mikkael A. Sekeres, Amit Verma, Amer M. Zeidan, Eytan M. Stein, Gabriela S. Hobbs, Lewis R. Silverman, Keith W. Pratz, Maximilian Stahl, Mrinal M. Patnaik, Joshua F. Zeidner, Valeria Santini, Marina Kremyanskaya, Andrew H. Wei, Gail J. Roboz, David T. Bowen, Harry P. Erba, Elizabeth A. Griffiths, Aziz Nazha, Mark L. Heaney

Publikováno v: The Lancet. Haematology
The Lancet Haematology

Summary The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e65ab9f973fa03e20914c7ef5ccd36f9
http://hdl.handle.net/2158/1208093

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání